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INTRODUCTION
Colorectal cancer is the third most common cancer in the
United States. About 146,940 new cases of colorectal cancer
are reported each year, with 56,730 deaths among them (1).
Metastatic spread to the liver is frequent in patients with colo-
rectal cancer, affecting 35-55% of patients (2).
Hepatic resection is considered the only potentially cura-
tive therapy for colorectal liver metastases. Unfortunately,
only 10-15% of patients will have lesions amenable to resec-
tion (3, 4). For the remaining majority of patients with unre-
sectable liver metastases, current available treatment modali-
ties are limited to chemotherapy, immunotherapy, and inter-
stitial therapy. These therapies, however, have not shown any
convincing proof for survival benefit. Thus, further research
on treatment modalities is necessary to enhance effectiveness
of the treatment of colon cancer metastatic to the liver.
In 1979, p53 protein was first described as a 53 kilodalton
nuclear phosphoprotein that combined to the simian virus 40
(SV40) large tumor antigen in SV40-transformed cells (5).
P53 is located on the short arm of chromosome 17 (the region
17p13), which contains 393 amino acids. It was initially sug-
gested that p53 gene was an oncogene, as it was capable of
immortalizing cells by itself or transforming them in con-
junction with the ras oncogene (6). p53 has an important role
in the genesis or progression of both colorectal and hepato-
cellular cancers and it is mutated in about half of all human
tumors (7-10). Most often, these are missense mutations with
loss of the remaining allele. This is the most frequent genetic
change in human cancer. Among the other half of patients
where p53 is wild type, inactivation of other components of
the p53 signaling pathway may occur, and thus render p53
nonfunctional (11). Wild-type p53 protein in p53 mutated
tumor cells induces either apoptosis or cell cycle arrest at both
the G1 and G2/M cell cycle check points (10, 12-15). 
This study was designed to evaluate the tumor response of
allografted colorectal tumor treated with Ad5CMV-p53 in
vivo in the subcutaneous tissue of rat. In previous studies,
human colon cancer cells were administered in immunosup-
pressed rats. We, however, administered rat colon cancer cells
in rats with a healthy immune system, in order to exclude
possible rejection reaction and changes in the immune system.
By introducing foreign nucleic acid sequences into selected
cells in the tissue, gene therapy for cancer patients aims to
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In vivo Recombinant Adenovirus-mediated p53 Gene Therapy in a
Syngeneic Rat Model for Colorectal Cancer
The p53 gene has a significant role in controlling genomic stability of cancer. The
purpose of this study was to evaluate the tumor response of allograft colorectal tumor
treated with Ad5CMV-p53 in a syngeneic rat model. Two weeks after the inocula-
tion of WB-2054-M5 tumor cells in the flank of rats, rats were randomly assigned
by tumor size to one of three groups (n=18 in each): phosphate buffered saline
(PBS), Ad5CMV, and Ad5CMV-p53. Recombinant adenovirus or PBS was adminis-
tered through intratumoral injection at three divided doses every other day for 4
weeks. Apoptosis of the tumors was evaluated using TUNEL assay. After 2 and 4
weeks of treatment, the volume (cm
3) of tumors in PBS, Ad5CMV, and Ad5CMV-
p53 was as follows: 2 week: 1.66±0.43, 1.40±0.47, 0.75±0.26 (p<0.001), 4
week: 4.41±0.88, 3.93±1.86, 2.33±0.51 (p<0.001). Tumor growth showed no
statistically significant difference between the PBS and Ad5CMV groups (6-week
vol. p=0.32). The TUNEL assay results revealed more apparent apoptotic cells in
Ad5CMV-p53-treated tumors than in other groups. Growth of allograft colorectal
cancer in the syngeneic rat model was significantly suppressed by intratumoral
Ad5CMV-p53 gene therapy. These results demonstrate that gene replacement
therapy with p53 may provide a novel modality of treatment in conjunction with
other present treatments for metastatic colorectal cancer.
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correct or inhibit key mutations that cause tumor growth. A
variety of abnormalities of cancer can be identified at a genetic
level. Thus genetic control of tumor cells represents a promis-
ing new area in the management of cancer.  
MATERIALS AND METHODS
Tumor cell line and cell preparation
WB-2054 is a poorly differentiated mucin-producing colon
adenocarcinoma which is induced by administration of 1,2-
dimethylhydrazine to WF×BN F1 rats (16). WB-2054-M5
is a fifth generation metastatic variant derived through serial
applications of the Fidler hypothesis in our laboratory (17, 18).
WB-2054-M5 cells remained frozen in liquid nitrogen until
2-3 weeks prior to the experiment. The cells were then thaw-
ed, placed in culture media RPMI 1640 with 10% fetal calf
serum, 20 mM L-glutamine, 1,000 U/mL penicillin, and 1
mg/mL streptomycin (Bio-Whittaker, Walkersville, MD,
U.S.A.). The cells were grown in 5% CO2: air mixture in
tissue culture flasks (75 cm2) at 37℃ for 3-4 days until they
reached the logarithmic phase of growth. Then, the cells were
enzymatically detached using 0.25% trypsin-EDTA mixture
(Bio-Whittaker) for 20 min. Trypan blue exclusion was used to
determine viable cell counts. Cells were prepared for subcuta-
neous inoculation by resuspension in 5×106 cells/500 L of
DPBS (Dulbecco’s phosphate buffered saline: Bio-Whittaker).
Preparation of Ad5CMV, Ad5CMV-p53
Ad5CMV and Ad5CMV-p53, supplied by Introgen Ther-
apeutics, Inc., had 2.48×1012 viral particles (vps) in 1 mL
of frozen viral suspension of phosphate buffered saline with
10% (v/v) glycerol. Prior to dilution, the Ad5CMV-p53 vials
remained frozen at -60℃ to -80℃. Drug handling precau-
tions for cytotoxic drugs, universal precautions for infectious
material, and biological safety level 2 (BLS 2) guidelines were
observed. After being removed from the freezer, the Ad5CMV-
p53 vial was immediately placed on wet ice. Dose was pre-
pared under a biological safety cabinet.
Evaluation of gene transduction of adenovirus in vitro 
Each tumor cell line has different transduction efficiency
of the adenoviral vector (19). WB-2054-M5 cells were plat-
ed at a density of 200,000 cells/well in 6-well plates in trip-
licate. Ad5CMV- -gal virus was used to infect the tumor
cells at different vps of 1×108, 2×108, 4×108, and 1×109.
After 48 hr, cells were washed with PBS at 4℃, fixed with
ice-cold 1.25% glutaraldehyde, and stained with X-gal solu-
tion (20). Transduction capabilities were assessed by deter-
mining the percentage of X-gal-positive cells (blue) which
indicates  -galactosidase activity (13).
Hexosaminidase assay
WB-2054-M5 cells were plated at a density of 100,000
cells/well in 6-well plates in duplicate. The cells were infect-
ed with Ad5CMV-p53 (5×108 vp), Ad5CMV (5×108 vp)
or PBS as a control at days 1, 2, 3, 4, and 5 of incubation at
37℃. Following infection, cell growth of each treatment
group was measured colorimetrically using the hexosamini-
dase assay (21) in duplicate wells everyday for 5 days. Hex-
osaminidase is a ubiquitous lysosomal enzyme thought to
be involved in the degradation of glycosylated cellular con-
stituents. A chromogenic substrate of this enzyme is used to
count cell number. The absorbance of light waves (405 nm)
showed a linear, direct proportion to the number of cells pre-
sent and the time allowed for the reaction.
Cell-Growth assay
In vitro study of cell growth using cell proliferation anal-
yses was done to evaluate the effect of adenovirus-mediated
wild-type p53 expression. Theoretically, this analysis allows
determination of whether the transfection of wild-type p53
suppresses tumor cells before performing an in vivo experi-
ment.
WB-2054-M5 cells were plated at a density of 100,000
cells/well in 6-well plates in quadruplicate. The cells were
infected with Ad5CMV-p53 (5×108 vp), Ad5CMV (5×108
vp), or PBS as a control at days 1, 2, 3, 4, and 5 of incubation
at 37℃. Cell growth of each treatment group was measured
by counting cells in quadruplicate wells for 5 days. Viabili-
ty of cells was assessed by trypan blue exclusion.
Cell-Cycle assay
WB-2054-M5 cells were plated at a density of 200,000
cells in 60-mm dishes in duplicate. The cells were infected
with Ad5CMV-p53 (1×109 vp), Ad5CMV (1×109 vp), or
PBS as a control at days 1, 2, and 4 of incubation at 37℃.
The DNA content of trypsinized cells were analyzed using
the FACScan (Becton Dickinson, Franklin Lakes, NJ, U.S.A.),
after staining with propidium iodide using a Cycletest kit
(Becton Dickinson). Cell-cycle distribution was determined
using Cell Fit Software (HP340 Series 9000 Workstation).
Pulse processing was used to gate out dead cells.
Apoptosis fluorescent staining assay
WB-2054-M5 cells were plated at a density of 200,000
cells in 60-mm dishes. The cells were infected with Ad5CMV-
p53 (1×109 vp), Ad5CMV only (1×109 vp), or PBS as a
control at days 1, 2, and 4 of incubation at 37℃. Trypsinized
tumor cells were mixed with fluorescent DNA-binding dyes
and examined by fluorescence microscopy to visualize and
count cells with aberrant chromatin organization. Acridine836 J.-H. Baek, M.L. Agarwal, R.R. Tubbs, et al.
orange and ethidium bromide were used to determine how
many cells have undergone apoptosis and to produce an apop-
totic index that was calculated by the following formula: apop-
totic cells divided by the total cells ×100.
Allograft subcutaneous tumor model
Allograft tumors were induced by subcutaneous injection
of WB-2054-M5 tumor cells (5×106 cells/500  L) into the
flank area of the F1 hybrid rats under general anesthesia. Two
weeks after the inoculation, rats were randomly assigned by
tumor size to one of the three experimental groups: PBS,
Ad5CMV, and Ad5CMV-p53. Recombinant adenovirus (2×
1011 vp) or PBS was administered through intratumoral injec-
tion at three divided doses every other day. Each injection of
purified virus was diluted in a total volume of 250  L PBS
and gently administered using a 30-gauge hypodermic needle.
The F1 hybrids of female Wistar-Furth and male Brown-
Norwegian rats (WF×BN F1) which are syngeneic to the
tumor cell line WB-2054-M5 were used for the study. The
hybrid rats were 12-14 weeks after birth. Parent rats were
obtained from Harlan Sprague Dawley Inc. (Indianapolis,
IN, U.S.A.). All animals were treated in accordance with the
National Research Council’s Guide for Care and Use of Lab-
oratory Animals and Cleveland Clinic Foundation Animal
Review Committee. Rats were provided with food and water
ad libitum throughout the course of the experiment.
F1 Rats were inoculated at week 10 after birth. Intramus-
cular ketamine (60 mg/kg) and xylazine (8 mg/kg) was used
for general anesthesia. The rodents’ flank was shaved and
incised 3 mm to inoculate 5×106 tumor cells suspended in
500  L of DPBS into the subcutaneous tissue. Cells were
injected in a single location within the tissue using a 30-gauge
hypodermic needle. The skin was then sutured with prolene
4.0. Animals were kept under close monitoring from anes-
thesia until recovery.
To see tumor growth, the size of the tumors was measured
twice a week following treatment. Vernier calipers was used
for size measurement. Tumor volume (the tumor is assumed
to be ellipsoid in shape) was calculated according to the ellip-
soid formula (4 /3×abc, a: length/2, b: height/2, c: width/2).
After rats were sacrificed with an overdose of phenobarbital
(100 mg/kg intravenously) after 4 weeks of treatment, the
tumors in the subcutaneous tissue were excised. Tumor vol-
ume was measured three dimensionally by a blinded exam-
iner. The tumors were also weighed using Mettler AE 100,
Mettler-Toledo, Inc. 
Tumors were harvested 24 hr after final treatment of 3 rats
from each group. The in situ TUNEL assay was performed on
paraffin-embedded tissue sections (22). In the process, con-
ventional histological sections were nick end labeled with
biotinylated poly dU, introduced by terminal deoxytrans-
ferase, and then stained using streptavidin-conjugated alka-
line phosphatase.
Apoptag Peroxidase In Situ Apoptosis Detection Kit (Inter-
gen company) was used for the TUNEL assay for apoptotic
cell labelling. After deparaffinization, sections were incubat-
ed with 20 mL proteinase K for 15 min at room temperature
and then washed with dH2O. Endogenous peroxidase was
inactivated by covering the sections with 2 % H2O2 for 5 min
at room temperature. The sections were rinsed with PBS and
immersed in equilibration buffer for at least 10 sec. A work-
ing strength TdT enzyme was incubated in a humid cham-
ber at 37℃ for 1 hr. The reaction was terminated by trans-
ferring the slides to stop/wash buffer for 10 min and rinsing
with PBS. Anti-digoxigenin peroxidase conjugate was applied
to the slides for 30 min and rinsed with PBS. The sections
were covered with peroxidase substrate (DAB) for 3 min and
washed with dH2O. Then, counterstain was done using 0.5%
methyl green for 10 min at room temperature and washed
with dH2O. After washing with 100% n-butanol and mount-
ing, apoptosis was evaluated.
Statistics
The rats were randomized into three balanced treatment
groups. Tumor response of these groups were compared using
the one-way analysis of variance (ANOVA) which had a sig-
nificance level of 0.05. 
RESULTS
Evaluation of gene transduction of adenovirus in vitro
In order to determine the optimal transduction efficiency,
varying numbers of viral particles were transduced. Trans-
duction rate was defined by the percentage of cells staining
blue with  -galactosidase activity. At viral particle numbers
of 4×108 and 1×109 transduction rates of 82.4% and 100%
were obtained, respectively (Fig. 1).
Determination of the effect of Ad5CMV-p53 infection on
WB-2054-M5 cell growth
The hexosaminidase assay was used to determine the effect
of Ad5CMV-p53 infection on WB-2054-M5 cell growth.
Five days after the infection, growth of the tumor cells that
were infected with Ad5CMV-p53 was significantly inhibit-
ed (Fig. 2). The cell growth assay reinforced findings in Fig.
2 that growth inhibition of Ad5CMV-p53-infected tumor
cells  was more significant, compared with the cells infected
with only the viral vector Ad5CMV or only PBS (Fig. 3).
Effects of Ad5CMV-p53 infection on cell cycle and 
apoptosis in WB-2054-M5 cells
After transfection of p53 via the vector Ad5CMV-p53, WB-p53 Gene Therapy for Colorectal Cancer 837
2054-M5 cells accumulate during the G1 phase as there was
no progression into the S phase. By day 4 of incubation after
transfection, the cells exposed to Ad5CMV-p53 had a signif-
icantly larger G1/S ratio compared to the cells infected with
the viral vector alone or PBS (p<0.001) (Fig. 4). This is con-
sistent with the belief that p53 inhibits the growth of WB-
2054-M5 cells.
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Fig. 2. Effect of Ad5CMV-p53 infection on the growth of WB-2054-
M5 tumor cells by hexosaminidase assay. WB-2054-M5 cells were
plated at a density of 100,000 cells/well and infected with Ad5CMV-
p53 (5×10
8 vp), Ad5CMV (5×10
8 vp) or PBS as a control. Cell
growth in each treatment group was measured colorimetrically
using the hexosaminidadse assay in duplicate wells daily for 5
days following infection. The absorbance of light waves at 405 nm
showed a linear, direct proportion to the number of cells present
and the time allowed for the reaction. WB-2054-M5 cell growth is
significantly more inhibited in the Ad5CMV-p53-treated group, com-
pared to the Ad5CMV and PBS groups (p<0.001).
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Fig. 1. The percentage of WB-2054-M5 cells transduced at varying
amounts of viral particles. Cells were plated at a density of 200,000
cells/well and Ad5CMV- -gal virus was used to infect the tumor cells
at varying viral particle number. After 48 hr cells were stained with
X-gal solution.Their transduction capability was assessed by deter-
mining the percentage of X-gal positive cells. 
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Fig. 4. Comparison of mean G1/S ratio in cells infected with Ad5-
CMV-p53, Ad5CMV, or PBS. WB-2054-M5 cells were plated at a
density of 200,000 cells in 60-mm cell plates and infected with
Ad5CMV-p53 (1×109 vp), Ad5CMV (1×109 vp), or PBS as a con-
trol. Cell cycle distribution was assessed at days 1, 2, and 4 of
incubation by analyzing DNA content using a FACScan, Cycletest
kit and Cell Fit Software. Dead cells were gated out by pulse pro-
cessing. The G1/S ratio is significantly increased in the cells infect-
ed with Ad5CMV-p53 (p<0.001).
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Fig. 3. Effect of Ad5CMV-p53 infection on the growth of WB-2054-
M5 tumor cells in the cell growth assay. WB-2054-M5 cells were
plated at a density of 100,000 cells/well and were infected with
Ad5CMV-p53 (5×10
8 vp), Ad5CMV (5×10
8 vp), or PBS as a con-
trol. Cell growth in each treatment group was measured by count-
ing cells daily in quadruplicate. Growth of WB-2054-M5 cells is
significantly inhibited by Ad5CMV-p53 infection (p<0.001).
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In addition to growth inhibition, tumor cells that were
transfected with Ad5CMV-p53 had a markedly larger per-
centage of cells undergoing apoptosis than those transfected
with Ad5CMV or PBS (p<0.001) (Fig. 5). To obtain an apop-
totic index (apoptotic cells/total cells ×100), the apoptosis
fluorescent staining assay was used to differentiate between
viable and nonviable cells within a given population.
Effects of intratumoral injection of AdCMV-p53 on 
allograft colorectal tumor
Fig. 6 demonstrates significant suppression of allograft colo-
rectal tumor after intratumoral injection of AdCMV-p53.
The data was obtained from 54 rats, 18 from each of three
treatment groups. PBS, Ad5CMV, or Ad5CMV-p53 were
administered at 2-weeks following subcutaneous tumor cell
injection. Tumor dimensions were recorded at a regular inter-
vals of 3 or 4 days over a 6-week span. Tumor volume was
obtained according to the ellipsoid formula. The volume of
the tumors in the PBS, Ad5CMV, and Ad5CMV-p53 groups
at week 4 and 6 was as follows: week 2: 1.66±0.43, 1.4±
0.47, 0.75±0.26 cm3 (p<0.001), week 4: 4.41±0.88, 3.93
±1.86, 2.33±0.51 cm3 (p<0.001). After adjustment for
age, rat weight at operation and tumor volume at week 2,
tumor growth of the Ad5CMV-p53 group was significantly
suppressed (p<0.001). There was no significant difference
between tumor volumes of the PBS and Ad5CMV groups
(6-week vol. p=0.32). In the TUNEL assay, we found more
apparent apoptotic cells in Ad5CMV-p53-treated tumors
than in other groups (Fig. 7) 24 hr after the final treatment
of 9 rats.
DISCUSSION
Colorectal cancer that metastasizes into liver remains one
of the leading causes of cancer-related death in the United
States. Research focus has been on the tumor suppressor gene
p53 and its role in inhibiting tumor growth. p53 is mutated
in about half of all human tumors and about 70 % in colorec-
tal cancers (7-9, 13). Mutant p53 has also been reported to
decrease the expression of vascular endothelial growth factor
(23). Mutation of p53 is considered to be an important tumor
biology factor in colorectal cancer and other malignancies. 
Various viruses and liposomes have been introduced as a
means to deliver a specific gene. In particular, adenoviruses
have been widely adopted as vectors for gene therapy in both
animal and human trials. Drazan et al. (24) described the
appeal of replication-defective adenovirus for use in hepatic
gene therapy: 1) high purity concentrates of adenovirus vec-
tors may allow for high multiplicity of infection in vivo, 2)
the shuttle vector can insert DNA sequences into hepatic
cells regardless of the organ’s physiologic state, and 3) spe-
cific sero-types are highly hepatotropic and rapidly endocy-
tosed by eukaryotic cells. Recombinant adenoviruses have
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Fig. 5. Comparison of the percentage of apoptotic cells in the cell
groups infected with Ad5CMV-p53, Ad5CMV, or PBS. WB-2054-
M5 cells were plated at a density of 200,000 cells in 60-mm plates
and infected with Ad5CMV-p53 (1×10
9 vp), Ad5CMV (1×10
9 vp),
or PBS as a control. Cells were assessed for apoptosis at days
1, 2, and 4 of incubation by exposure to fluorescent DNA binding
dyes and by fluorescence microscopy to count cells with aberrant
chromatin. An apoptotic index was developed: apoptotic cells/total
cells ×100.
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Fig. 6. The effect of intratumoral injection of AdCMV-p53, AdCMV,
or PBS on the volume of allograft colorectal tumor. Allograft tumor
cells were injected subcutaneously into the flank of F1 hybrid rats.
Two weeks after inoculation, rats were randomly assigned to PBS,
Ad5CMV, or Ad5CMV-p53. Intratumor injection of recombinant
adenovirus (2×10
11 vp) or PBS was done at 3 divided doses every
other day. Then, tumor volume was measured. The outcome of
the Ad5CMV-p53 group is significantly different from the other
two groups (2 week: p<0.87, 3-6 Week: p<0.001), but there is no
statistically significant difference between the outcomes of the
PBS and Ad5CMV groups (6-week vol. p=0.32).
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various advantages over alternative delivery methods in that
they usually do not insert their DNA into the genome of
the host cell and that they are highly efficient modes of gene
transfer.
Drazan et al. described the advantages of replication-defec-
tive adenovirus for hepatic gene therapy (24, 25). They em-
phasized the safety of adenovirus-mediated tumor-suppres-
sor transduction into hepatocytes and over-expression of wild-
type p53 transfected into quiescent and regenerating hepa-
tocytes. Zhang et al. assessed the infectivity and cytotoxicity
of Ad5CMV-p53 on human lung cancer cells and suggested
that Ad5CMV-p53 at a dose that is effective in cancer cells
is not detrimental to normal cells (26). The maximum tol-
erated dose of Ad5CMV-p53 in patients was the maximum
attainable dose: 1×1011 pfu. According to the data by Intro-
gen Therapeutic, Inc., there was no treatment-related mortali-
ty or clinical signs of harm in rats and mice at dose of 1.43
×1011 pfu/kg. After direct intratumoral injection of recom-
binant adenovirus (total 2×1011 vp/rat, 1 pfu=20 vp), there
was no evidence of toxicity in the earlier mentioned in vivo
experiments.
It was necessary to determine the ideal number of viral par-
ticles (vps) administered in order to get optimal transduction
rates and to assess tumor cell growth in cells treated with
Ad5CMV-p53. A transduction rate of 100% was obtained
at the vp number of 1×109. At this vp level, it was possible
to assess growth of tumor cells using the hexosaminidase assay
and the cell growth assay. Prior to performing the in vivo
experiment, the ability of transfected wild-type p53 to sup-
press tumor cell growth can be assessed this way. WB-2054-
M5 cells were more significantly inhibited by Ad5CMV-p53
than by PBS and Ad5CMV in both assays. In vitro cell pro-
liferation analyses was done to evaluate the effect of adeno-
virus-mediated wild-type p53 expression. Theoretically, this
analysis allows determination of whether the transfection of
wild-type p53 suppresses tumor cells before performing the
in vivo experiment. It is now well established that p53 induces
growth arrest either at G1 or apoptosis (11). In the cell cycle
assay, the G1/S ratio was markedly increased in the Ad5CMV-
p53 group. This is consistent with the findings that p53 inhi-
bits growth of WB-2054-M5 cells. Loss of viability, whether
it be the result of a necrotic processs or apoptotic process, is
Fig. 7. The H-E staining & TUNEL staining of WB-2054-M5 allograft tumors. Intratumoral injections of recombinant adenovirus (2×10
11 vp)
or PBS was done at three divided doses every other day. The tumors were harvested 24 hours after the final treatment and assessed
using the TUNEL assay. Apoptotic cells were more apparent in the Ad5CMV-p53-treated group than two other groups. (A) the H-E stain-
ing (poorly differentiated adenocarcinoma), (B) PBS-treated tumors, (C) Ad5CMV-treated tumors, (D) Ad5CMV-p53-treated tumors. Origi-
nal magnification, (A) ×200, (B-D) ×400.
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often defined as loss of membrane integrity. Necrosis refers
to the morphology usually associated with accidental cell
death, while apoptosis is seen when cell death is programmed
or physiologically regulated. Determination of whether a cell
dies by apoptosis as opposed to necrosis can be best made by
examining the distinct structural changes in the cell’s chro-
matin, which occur prior to lysis of the membrane. The num-
ber of apoptotic cells in WB-2054-M5 cells after transfection
of wild-type p53 increased and the apoptotic index marked-
ly increased in the Ad5CMV-p53 group. 
Many studies have been done to see the effect of p53 gene
therapy on various tumors. Some researchers reported that
growth of human head and neck cancer cells in nude mice
was suppressed after the introduction of a wild-type p53 gene
via a recombinant adenovirus (19, 27, 28). Ad5CMV-p53
has been shown to suppress growth of human lung cancer
tumor in the orthotopic lung cancer model of nude mice (26).
It has also been reported that Ad5-p53 suppresses the tumori-
genic potential of human glioblastoma cells and inhibits cell
growth in the rodent 9L glioma brain tumor (4, 13). Spitz
et al. demonstrated that human colorectal tumor was signif-
icantly suppressed and apoptosis was induced in mice follow-
ing direct intratumoral injection of adenovirus-mediated wild-
type p53 gene (13). Ad5CMV-p53 inhibited tumor growth
during and immediately after treatment. Harris et al. also
showed that Ad5-p53 in vivo suppressed tumor growth and
increased survival of nude mice bearing human colon cancer
that expresses mutant p53 (29). The latter two studies were
confined to xenograft subcutaneous tumors of colorectal can-
cer. In our experiments, a syngeneic rat model of allograft
subcutaneous tumor was created and the tumor response after
direct intratumoral injection of Ad5CMV-p53 for colorectal
carcinoma was evaluated.
The positive results from the in vitro experiments encour-
aged the recombinant adenovirus-mediated p53 gene thera-
py in the syngeneic rat model for colorectal cancer. Tumor
growth in the Ad5CMV-p53 group was significantly more
suppressed compared to the other two groups. No difference
in tumor growth was seen between the PBS and the Ad5CMV
groups, indicating that toxicity to tumor cells was not mediat-
ed by the recombinant adenovirus alone. Harris et al. showed
that intratumoral injection of recombinant adenovirus resulted
in nonuniform transgene expression in subcutaneous tumors
(29). 
The TUNEL staining has been used for the in vivo analy-
sis of apoptosis (13, 22, 30, 31). The TUNEL assay is based
on direct, specific, in situ labelling of DNA breaks in the
nuclei. It provides the in situ visualization of apoptosis at a
single-cell level, while protecting tissue architectures. In our
study, the TUNEL assay demonstrated more apoptotic cells
in Ad5CMV-p53 treated tumors compared to the other two
groups. 
These results support a role for p53 gene therapy as an
adjunct to current therapies available for cancers with muta-
tions in this tumor suppressor gene. Ad5CMV-p53 demon-
strated effective suppression of colorectal tumor in the allo-
graft subcutaneous tumor model of rat. The important role
of adenovirus-mediated wild type p53 gene transfer has been
shown in several realms of tumor biology. Down-regulation
of endothelial growth factor expression and thus inhibition
of angiogenesis in human colon cancer can be achieved with
wild type p53 gene transfer (23). This study employed ad-
vanced technology allowing for direct gene transfer into liv-
ing animals and emphasized an opportunity to develop novel
modalities of treatment for malignant tumors.
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